ArticleCancer immunology research2021
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance.Cancer research · 2026Article
- RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11bNature communications · 2026Article
- RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.Cancer immunology research · 2026Article
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy.Cancers · 2025Article
- Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal Cancer.International journal of molecular sciences · 2025Article
- Modulation of Spliceosomal Proteins hnRNPH1 and H2 Increases Melanoma Cell Pro-Inflammatory Signaling In Vitro.Biomolecules · 2025Article
- Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma.Biomolecules · 2025Article
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.Journal of translational medicine · 2024Review
- Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.Cell reports. Medicine · 2024Article
- Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs.Acta neuropathologica communications · 2024Article
- New clinical trial design in precision medicine: discovery, development and direction.Signal transduction and targeted therapy · 2024Review
- Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.bioRxiv : the preprint server for biology · 2023Article
- Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.Journal for immunotherapy of cancer · 2023Article
- PAK1 and Therapy Resistance in Melanoma.Cells · 2023Review
- The OSUMMER lines: A series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6.Pigment cell & melanoma research · 2023Article
- TargetingJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Cell death, therapeutics, and the immune response in cancer.Trends in cancer · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Manali S PhadkeThe Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Zhihua ChenThe Department of Biostatistics and Bioinformatics, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Jiannong LiThe Department of Biostatistics and Bioinformatics, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Eslam MohamedThe Department of Immunology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Michael A DaviesThe Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Inna SmalleyThe Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6796-9145
Derek R DuckettThe Department of Drug Discovery, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Vinayak PalveThe Department of Drug Discovery, The Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-8221-5018
Brian J CzernieckiThe Department of Immunology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Peter A ForsythThe Department of Neurooncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-3756-8594
David NoyesThe Department of Malignant Hematology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Dennis O AdeegbeThe Department of Immunology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Zeynep ErogluThe Department of Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Kimberly T NguyenThe Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-5144-0653
Kenneth Y TsaiThe Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Uwe RixThe Department of Drug Discovery, The Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-8242-2770
Christin E BurdDepartment of Cancer Biology and Genetics, Ohio State University, Columbus, Ohio.
Yian A ChenThe Department of Biostatistics and Bioinformatics, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Paulo C RodriguezThe Department of Immunology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.
Keiran S M SmalleyThe Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida. keiran.smalley@moffitt.org.
Moffitt Cancer Center · USCancer Genetics (United States) · USThe University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MProject 4P01CA250984 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$10.1MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MTissue, Pathology and BioinformaticsP50CA168536 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI MULE, JAMES J. · 2013 to 2017
$8.5MFunctional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligandsR01CA233512 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2019 to 2023
$2.0MStress Pathways in Tumors Drive Global MDSC Activity and Survival through ChopR01CA184185 · NCI · LSU HEALTH SCIENCES CENTER · PI RODRIGUEZ, PAULO CESAR · 2015 to 2019
$1.8MDefining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy EscapeR00CA226679 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, INNA · 2020 to 2022
$747kInvestigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancerK22CA222669 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ADEEGBE, DENNIS O · 2018 to 2020
$547kModeling and Targeting Adaptive Signaling Responses in Single NRAS Mutant Melanoma CellsR21CA198550 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, KEIRAN · 2015 to 2016
$422kUsing Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastasesR21CA216756 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI FORSYTH, PETER ALEXANDER, SMALLEY, KEIRAN · 2017 to 2018
$412kDefining the role of metabolic heterogeneity in melanoma dissemination and therapy escapeK99CA226679 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, INNA · 2018 to 2019
$197kNCI NIH HHS K22 CA222669NCI NIH HHS K99 CA226679NCI NIH HHS P01 CA250984NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA168536NCI NIH HHS R00 CA226679NCI NIH HHS R01 CA184185NCI NIH HHS R01 CA233512NCI NIH HHS R21 CA198550NCI NIH HHS R21 CA216756NCI NIH HHS T32 CA009666
Abstract
Immunotherapy (IT) and targeted therapy (TT) are both effective against melanoma, but their combination is frequently toxic. Here, we investigated whether the sequence of IT (anti-PD-1)→ TT (ceritinib-trametinib or dabrafenib-trametinib) was associated with improved antitumor responses in mouse models of
Indexed as
AnimalsAntineoplastic AgentsCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalFemaleImidazolesImmunotherapyMelanomaMiceMice, Inbred C3HMice, Inbred C57BLMolecular Targeted TherapyMonomeric GTP-Binding ProteinsMutationOximesAntineoplastic AgentsBraf protein, mouseceritinibdabrafenibImidazolesMonomeric GTP-Binding ProteinsNras protein, mouseOximesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-rafPyridonesPyrimidinesPyrimidinonesSulfonestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.